Research chemicalStimulantResearch chemicalSubstituted amphetamine

3-Fluoroamphetamine (3-FA)

Also known as 3-FA · meta-fluoroamphetamine · PAL-353

Written by enwyReviewed 4 Aug 20262 sources0 comments

3-Fluoroamphetamine (3-FA) is a positional isomer of 4-FA and a fluorinated amphetamine stimulant. It is reported to be more dopaminergic and stimulant-like than 4-FA with less entactogenic character. Human data is essentially limited to anecdote and isolated case reports.

01 Overview

3-FA (3-fluoroamphetamine) is the meta-fluoro isomer of fluoroamphetamine. Compared with the 4-fluoro isomer, users describe a more purely stimulating, amphetamine-like profile with more pronounced cardiovascular stimulation and comedown.

There is almost no controlled human research. What is known comes from receptor-binding and animal studies plus scattered user reports and analytical case work. Its safety profile, effective dose range and neurotoxic potential are uncharacterised, and it should be regarded as a novel, poorly studied stimulant.

02 Mechanism

Releases and inhibits reuptake of dopamine and noradrenaline, with weaker serotonergic activity than 4-FA. The meta-fluoro position favours catecholamine over serotonin release.

03 Dosing

Tier	Dose	Route	Notes
Light	15–30 mg	Oral	Anecdotal; considered more potent than 4-FA.
Common	15–40 mg	Insufflated	Faster onset, harsh; high redosing risk.
Common	30–60 mg	Oral	Long duration reported; strong stimulation.

04 Effects

Effect	Magnitude	Evidence
Strong stimulationMarked energy, focus and wakefulness, more amphetamine-like than 4-FA.	strong	Anecdotal
EuphoriaDopaminergic euphoria without much of the empathogenic warmth of 4-FA.		Anecdotal
Appetite suppressionReduced hunger during the active period.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Prolonged comedown and insomniaLong duration causes extended sleep deprivation followed by fatigue, low mood and irritability.	Moderate	Very common	Anecdotal
Compulsive redosingDopaminergic reinforcement drives repeated dosing and dose escalation.	Moderate	Common	Anecdotal
Cardiovascular strainTachycardia and hypertension expected from its pharmacology; specific cardiotoxic events poorly documented but plausible.	Severe	Common	Unconfirmed

06 Legal status

Germany

NpSG (New Psychoactive Substances Act)

Captured by German amphetamine-class NPS legislation. · as of Jan 2026

United States

Not federally scheduled by name

Potentially an analogue under the Federal Analogue Act. · as of Jan 2026

07 References

New psychoactive substances: fluorinated amphetaminesEUDA (European Union Drugs Agency)

Positional isomers of fluoroamphetamine: pharmacologyPubMed

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.